ArnoldBruceGelbMDFASCP, FCAP

Senior Clinical Trial Physician

Dr. Gelb is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
Bristol Myers Squibb
1000 Sierra Point Pkwy
Brisbane, CA 94005
Phone+1 415-717-4342

Accomplished Physician and Leader in Clinical Development, Translational Medicine and Pathology pharma/biotech R and D with significant therapeutic focus in antibody drug conjugates and immuno-oncology/oncology in select solid tumors and malignant hematology, and immunology. Leadership experience up to Executive Director with site head and Interim Chief Medical Officer responsibilities. Strengths include programmatic/strategic and project development, multi-site project management, clinical informatics, effective communications with physicians/ key thought leaders, in-depth health industry knowledge, superior analytical and financial skills, and significant experience as a published scientific/medical author and speaker.

University of California (San Francisco)Fellowship, Hematopathology, 1994 - 1995
University of California (San Francisco) School of MedicineResidency, Laboratory Medicine (Clinical Pathology), 1993 - 1994
Stanford Health CareFellowship, Immunopathology, 1991 - 1993
Stanford Health Care-Sponsored Stanford University Surgical PathologyFellowship, Selective Pathology, 1990 - 1991
Stanford Health Care-Sponsored Stanford UniversityResidency, Pathology-Anatomic and Clinical, 1988 - 1990
University of ChicagoInternship, Internal Medicine, 1987 - 1988
Stanford University School of MedicineClass of 1987

PubMed

4 citations
Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient.
Matthew McCord, Rimas V. Lukas, Christina Amidei, Nathan Demars, Arnold Gelb
Neuro-Oncology Advances. 2021-01-01
168 citations
Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial.
E. Antonio Chiocca, John S. Yu, Rimas V. Lukas, Isaac H. Solomon, Keith L. Ligon
Science Translational Medicine. 2019-08-14
65 citations
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: Phase 1b results f...
Hyun Cheol Chung, Hendrik Tobias Arkenau, Jeeyun Lee, Sun Young Rha, Do Youn Oh
Journal for Immunotherapy of Cancer. 2019-02-04

Journal Articles

Posttransplant lymphoproliferative disorders in patients undergoing pediatric liver transplantation: a clinicopathologic study.
Koh BY, Rosenthal P, Medeiros LJ. Zhou Y, Osorio RY, Roberts JP, Ascher NL, Gelb AB, Cancer

Books/Book Chapters

Chapter: The Molecular Biology of Leukemias
Page 427 - 460Gelb, A.B., Medeiros, L.J.Editors: Coleman, W., Tsongalis, G..Humana Press, TotowaEdition 1,

Abstracts/Posters

Comparison of PTEN protein loss and PI3K gene mutation status in breast cancer.
Gelb, A.B., Deng, L., Freemna, V.A., Astrow, S.A., AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Denver, CO

Senior Clinical Trial Physician, Bristol-Myers Squibb2020 - Present
Executive Director, Ziopharm Oncology, Inc.Clinical Development & Medical Monitor2018 - 2020
Senior Director, EMD Serono R&D InstituteGlobal Early Development2015 - 2018